Stayble Therapeutics reaches important milestone - phase IIb-study fully recruited
Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the last patient has been recruited in the ongoing phase IIb clinical trial of STA363 for chronic disc-related low back pain. Recruitment is thereby completed. The patients will be followed for 12 months after inclusion. Final results from the study are expected to be available in Q4 2023 after the Company has compiled and analyzed data from all treated patients in the study.The primary objective of the study is to investigate the effect of STA363 on ongoing pain (primary endpoint) in patients suffering from chronic